|
Synonyms: campath 1H | Campath® | campath-1H | Lemtrada®
alemtuzumab is an approved drug (FDA (2001), EMA (2013))
Compound class:
Antibody
Comment: CAMPATH-1 (CD52) antigen inhibitor. Functionally, alemtuzumab causes depletion and then recovery of the immune system.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. 
View more information in the IUPHAR Pharmacology Education Project: alemtuzumab |
| Bioactivity Comments |
| The necleotide sequences for the CAMPATH-1 antibody were originally identified by Crowe et al. (1992) [1], and this article reports the ADCC effector function of the antibody against K422B lymphoma cells. The reported nucleotide sequences were used to generate an antibody with swapped anti-CAMPATH domains, described in patent US7923538 [4]. The constructed antibodies exhibited improved complement-dependent cytotoxic activity (CDC) and antibody-dependent cell-mediated cytotoxic activity (ADCC) compared to Campath1H-IgG. Affinity data for the interaction between the antibody and the CAMPATH-1 antigen is not provided in either the original article or in patent US7923538 [5]. |
| Selectivity at other protein targets | ||||||||||||||||||||||||||||||||||
| Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||
